Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Take a brief audio tour around Scrip's Five Must-Know Things, this time for the business week ended 23 October 2020.
In this edition, we take a look at generic impact on one firm’s sales outlook, a major legal settlement in the US, a potential European product approval, corporate performance in India, and mixed results at two big multinationals.
These and other Informa Pharma Intelligence podcasts are available on SoundCloud, Apple Podcasts and TuneIn and also via any Alexa-enabled smart speaker or the Alexa app. Just say "Alexa - ask Informa Pharma Intelligence to find podcasts."
Stories mentioned in this episode:
(Also see "Tecfidera Headwinds Could Mean Cuts At Biogen, Unless Aducanumab Succeeds" - Scrip, 21 Oct, 2020.)
(Also see "Purdue's $8.3bn Settlement With DOJ Requires Reconstitution As Public Benefit Company" - Scrip, 21 Oct, 2020.)
(Also see "Novartis’ Cholesterol Drug Inclisiran Closes In On EU Approval" - Scrip, 16 Oct, 2020.)
(Also see "India Q2 Preview: Glenmark, Cipla Emerge Stronger" - Scrip, 20 Oct, 2020.)
(Also see "Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results" - Scrip, 20 Oct, 2020.)